BioAtla Investor Presentation Deck

Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: Melanoma, NSCLC and SCCHN bicatla Total patients (n = 100) ● Phase 2 - Melanoma / NSCLC ● Melanoma: PD1 failure - (n = 40) Q2W NSCLC: PD1, EGFR or ALK failure - (n = 60) Q2W or 3Q4W Monotherapy and Combination with PD-1/L1 Use to determine TmPS cut-off and potential registrational study design Phase 2 - SCCHN Total patients (n = 40) SCCHN: Prior treatment with a PD-1/L1 inhibitor either administered alone (n = 20) or in combination with Platinum (n = 20) - Q2W ● Monotherapy Use to determine TmPS cut-off and potential registrational study design BioAtla| Overview 32

View entire presentation